Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
WYN | Ann: Wynyard Group Limited (in liquidation) (“WYN”) – Delisting | 26/05/17 | 0 | 745 | |||
|
|||||||
WYN | Ann: Wynyard Group Announces Intention to Delist | 24/05/17 | 0 | 745 | |||
|
|||||||
WYN | Ann: Wynyard Announces Voluntary Administration | 02/03/17 | 23 | 4.3K | |||
|
|||||||
WYN | Ann: Creditors place Wynyard Group Limited into liquidation | 09/02/17 | 0 | 919 | |||
|
|||||||
WYN | Ann: Sale of the Cognevo business division. | 23/11/16 | 1 | 1.3K | |||
|
|||||||
WYN | Ann: Wynyard Group Limited (Administrators Appointed) | 26/10/16 | 0 | 836 | |||
|
|||||||
WYN | Ann: Wynyard Group Limited (“WYN”) – Suspension of Securities | 25/10/16 | 0 | 786 | |||
|
|||||||
WYN | Ann: Wynyard Group Market Update | 25/10/16 | 11 | 3.1K | |||
|
See All Discussions